2010
Docetaxel
Phillips C, Petrylak D. Docetaxel. 2010, 133-146. DOI: 10.1007/978-1-60327-829-4_12.Peer-Reviewed Original ResearchCastration-resistant prostate cancerAndrogen deprivation therapyProstate-specific antigenProstate cancerInitial androgen deprivation therapyFirst treatment regimenSecondary hormonal manipulationsStandard chemotherapy combinationTaxane combination therapyFirst-line treatmentUse of docetaxelProstate cancer screeningDeprivation therapyRecurrent diseaseChemotherapy combinationsDocetaxel therapyPSA responseTreatment regimenTreatment optionsCancer screeningDisease progressionHormonal manipulationBetter survivalInvestigational usesSurgical castration
1993
Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer
Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer. Cancer 1993, 71: 1098-1109. PMID: 7679039, DOI: 10.1002/1097-0142(19930201)71:3+<1098::aid-cncr2820711432>3.0.co;2-g.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntineoplastic AgentsBone NeoplasmsCisplatinClinical Trials as TopicCoumarinsDoxorubicinDrug Administration ScheduleDrug ResistanceFluorouracilHumansIntercalating AgentsMaleMethotrexateNeoplasm StagingPolyaminesProstate-Specific AntigenProstatic NeoplasmsRemission InductionSomatostatinConceptsDrug trialsAdvanced hormone-resistant prostate cancerHormone-resistant prostate cancerObjective response rateCombination of vinblastineMost cytotoxic agentsReliable disease markersNew drug trialsProstate cancer cellsCurrent reviewNew therapeutic agentsPartial remissionVisceral metastasesAdvanced adenocarcinomaCytotoxic chemotherapyObjective responseContinuous infusionNonresponsive tumorsMarginal efficacyHormonal manipulationProstate cancerNew agentsResponse rateCytotoxic drugsTherapeutic agents
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply